Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

herceptin
Mylan said Herceptin biosim Ogivri would launch at a "competitive discount." (Roche)

Much has been made of the challenges Roche's blockbuster oncology troika faces with U.S. biosimilars hitting the market in quick succession. So far, those challengers haven't made much of a dent in Roche's sales stateside––but a new contestant could help tip the scales.

Mylan and Biocon have launched their Herceptin copy, Ogivri, in the U.S., making it the second biosim on the market for Roche's blockbuster breast and stomach cancer drug. 

Mylan said in a release that Ogivri would hit the market at a "competitive discount" to Herceptin but did not disclose the list price for its 420-milligram and 150-milligram vials. 

"With regulatory approval for our biosimilar (Herceptin) in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care," Mylan President Rajiv Malik said in a statement. 

RELATED: Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.